Call for Abstract
Scientific Program
4th World Congress on Bioavailabity and Bioequivalence Pharmaceutical R & D Summit, will be organized around the theme “Advanced Discussions of the Current Issues & Analyzing the Novel Approaches of Bioavailability & Bioequivalence”
BABE-2013 is comprised of 12 tracks and 84 sessions designed to offer comprehensive sessions that address current issues in BABE-2013.
Submit your abstract to any of the mentioned tracks. All related abstracts are accepted.
Register now for the conference by choosing an appropriate package suitable to you.
- Track 1-1Generic drugs: Current claims and future directions
- Track 1-2Therapeutic equivalence of generic antibiotic drugs and controversies
- Track 1-3Food-effect bioavailability and fed bioequivalence studies
- Track 1-4Design and analysis of BA/BE studies
- Track 1-5Statistical evaluation in BA/BE studies
- Track 1-6Scaling approach for BA/BE studies
- Track 1-7Application of nanotechnology in BA/BE studies
- Track 1-8Bioequivalence trials and clinical endpoint studies
- Track 1-9Bioequivalence analysis of highly variable drugs
- Track 1-10Bioavailability and bioequivalence: FDA approaches and regulations
- Track 1-11Bioequivalence study for cancer drugs
- Track 1-12Bioavailability - applied studies and advances in methodology
- Track 2-1Identification and characterization of drugs
- Track 2-2Drug design, development, and therapy
- Track 2-3New strategies for drug development
- Track 2-4Epidemiology of drug interactions
- Track 2-5Biochemical mechanisms of drug toxicity
- Track 2-6Integrated product development and structure based drug design
- Track 2-7CNS drug development: Principles, transport kinetics, diseases, and methods
- Track 2-8Computer aided drug design
- Track 3-1Biosimilars and biowavers in BA/BE studies
- Track 3-2Innovations in bioanalysis: Drug discovery to drug development
- Track 3-3Chiral method for bioanalysis
- Track 3-4Pharmacokinetics/physicochemistry perspective
- Track 3-5Regulator tips for securing a biowaiver
- Track 3-6PK/PD modeling for drug discovery and development
- Track 3-7Applied biopharmaceutics and pharmacokinetics
- Track 4-1Poorly water soluble drugs
- Track 4-2Protein and peptide drugs
- Track 4-3Inconsistently absorbed drugs
- Track 4-4Drugs exhibiting a specific gut window
- Track 4-5Drugs undergoing extensive hepatic first-pass effect
- Track 4-6BA/BE of oral therapeutic macromolecular drug delivery
- Track 5-1Pharmacokinetic concepts in drug development
- Track 5-2Harmonisation of BA/BE studies and regulatory aspects
- Track 5-3BA/BE studies of pharmacokinetic drug interactions
- Track 5-4Role of clinical pharmacology department in conducting BA/BE studies and safety reporting requirement
- Track 5-5Role of pre-systemic effects on bioavailability
- Track 5-6Impact of variability in BE studies
- Track 5-7Unresolved issues in BA/BE regulations
- Track 6-1Sustained release dosage forms
- Track 6-2Targeted drug delivery systems
- Track 6-3Transdermal drug delivery systems
- Track 6-4Pulmonary drug delivery systems
- Track 6-5Topical and dermatological drug products
- Track 6-6Physiological factors affecting drug absorption
- Track 7-1Stability issues in bioanalytical method development
- Track 7-2Bioanalytical method development and validation for quantitation
- Track 7-3Advancement in quantitative bioanalysis by LC-MS
- Track 7-4Method development strategies to increase sensitivity of analytical instruments
- Track 7-5Bioanalysis in metabolomics and DMPK
- Track 7-6Advances in mass spectrometry methodology development
- Track 7-7Validation of a sensitive LC-MS/MS assay to quantify the biomarkers
- Track 8-1Functional foods and lipids
- Track 8-2Selenium bioavailability
- Track 8-3Micro and macro nutrients
- Track 8-4Fortified foods and dietary supplements
- Track 8-5Neutraceuticals
- Track 8-6Bioavailability of drugs
- Track 8-7Bioavailability of enzymes and co-enzymes
- Track 9-1Global generic market overview
- Track 9-2Regulatory aspects of BA/BE studies in special populations
- Track 9-3Environmental toxicology
- Track 9-4Safety monitoring boards and ethical committees for BA/BE studies
- Track 9-5Industry experience with the EMA bioequivalence guidelines
- Track 10-1Requirements for investigational new drug application
- Track 10-2Procedures for determining BA/BE of drug products
- Track 10-3Requirements for submission of BA/BE data
- Track 10-4Criteria for waiver of evidence of in vivo BA/BE measurements
- Track 10-5Differences in the in vitro and in vivo pharmacokinetic profiles: Examination of current bioequivalence
- Track 10-6Bioequivalence recommendations for specific products
- Track 11-1Relative and absolute bioavailability
- Track 11-2Factors influencing bioavailability
- Track 11-3Methods for in vitro dissolution and bioavailability assays
- Track 11-4Genetic factors affecting bioavailability
- Track 11-5Bioequivalence regulations
- Track 11-6Effects of infection/disease on bioavailability
- Track 12-1Biosimilars: Regulatory approach
- Track 12-2Skill set for biosimilars development
- Track 12-3Biosimilars therapeutics
- Track 12-4Commercialization or globalization of biosimilars
- Track 12-5Plant produced biosimilar products
- Track 12-6BCS & IVIVC based biowaivers
- Track 12-7Analytical strategies